LAWRENCE, Kan., Apr 07, 2014 (BUSINESS WIRE) -- Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its pan-RAF inhibitor LY3009120 (DP-4978), under development in collaboration with Eli Lilly. The Phase 1 trial will evaluate the safety, tolerability and initial efficacy of LY3009120 in cancer patients. Data demonstrating the preclinical activity of LY3009120 in cancer were recently presented at the New Drugs on the Horizon plenary session at the American Association for Cancer Research (AACR) national meeting, held April 5-9, 2014 in San Diego. LY3009120 emerged from a collaboration between Eli Lilly and Deciphera Pharmaceuticals, LLC. Deciphera received a $6 million development milestone for initiation of Phase 1 studies.
"We are pleased with Lilly's decision to advance LY3009120 into clinical development based on the encouraging preclinical data demonstrated to date and look forward to reporting on its future progress," says Deciphera CSO, Daniel Flynn. "This product candidate provides an important new option for cancer patients in need of durable inhibition of multiple RAF forms. This milestone also marks another significant event for Deciphera as a clinical stage oncology company."
LY3009120 is a small molecule kinase inhibitor that has been shown to inhibit known characterized RAF isoforms, and potentially blocks proliferation in both BRAF and RAS mutant cancer cells. LY3009120 broadly blocks signaling of cellular RAF homo/heterodimers including CRAF containing dimers, thus minimizing paradoxical pathway activation and resistance mechanisms associated with selective BRAF inhibitors. Such paradoxical pathway stimulation is associated with side effects of these selective B-RAF inhibiting drugs, including cutaneous squamous cell carcinoma and other hyperplasias. As a pan-RAF inhibitor, LY3009120 blocks aberrant cancer signaling through RAS protein mutations, known to be prevalent in approximately 30% of all human cancers.
Initiated in late 2013, the Phase I study of LY3009120 is in patients with advanced cancer or cancer that has spread to other parts of their body. More information, including enrollment criteria, can be found at http://clinicaltrials.gov/ct2/show/NCT02014116?term=neuroendocrine+cancer&recr=Open&no_unk=Y&lup_s=11%2F19%2F2013&lup_d=30
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, LLC is a clinical-stage biotechnology company developing improved kinase inhibitor treatments for cancer. Deciphera's small molecule therapeutics block a key cancer signaling mechanism in a way that is highly durable and resilient to mutational resistance, cutting off the ability of tumor cells to thrive and spread. Deciphera's proprietary platform represents an evolution from the successfully marketed classical Type 2 kinase inhibitor approach by providing more robust and durable kinase binding in dysregulated oncogenic disease states. Leveraging its distinct approach, Deciphera has intentionally focused its pipeline of cancer therapeutics on targeting kinases that play an important role in tumor communication with the surrounding tissue, known as the tumor microenvironment. Deciphera's pipeline of clinical candidates includes Rebastinib, a TIE2 kinase inhibitor currently in Phase 1 clinical development, DCC-2701, a MET/TIE2/VEGFR2 kinase inhibitor currently in Phase 1 clinical development, and LY3009120 (DP-4978), a pan-RAF inhibitor currently in Phase 1 clinical development in collaboration with Eli Lilly. Preclinical pipeline assets include DCC-2618, a pan-KIT inhibitor.
Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With corporate offices in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
For more information, please visit www.deciphera.com .
SOURCE: Deciphera Pharmaceuticals
The Yates Network
Gina Nugent, 617-460-3579